{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:26:28Z","timestamp":1776173188626,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"am","delay-in-days":320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005317","name":"Abell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024327","name":"Maryland Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100026287","name":"Open Society Institute-Baltimore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100026287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015693","name":"Purdue Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32DA007292"],"award-info":[{"award-number":["T32DA007292"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.josat.2023.208981","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T07:58:33Z","timestamp":1676015913000},"page":"208981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Higher buprenorphine dose associated with increased treatment retention at low threshold buprenorphine clinic: A retrospective cohort study"],"prefix":"10.1016","volume":"147","author":[{"given":"Lea","family":"Selitsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Nordeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Agus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan E.","family":"Buresh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2023.208981_bb0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jsat.2015.09.004","article-title":"The effect of a payer-mandated decrease in buprenorphine dose on aberrant drug tests and treatment retention among patients with opioid dependence","volume":"61","author":"Accurso","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.208981_bb0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes","volume":"52","author":"Bentzley","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"8","key":"10.1016\/j.josat.2023.208981_bb0015","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMp2017363","article-title":"A good place to start\u2014Low-threshold buprenorphine initiation","volume":"383","author":"Berk","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.josat.2023.208981_bb0020","first-page":"1964","article-title":"The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts medicaid beneficiaries with opioid dependence","volume":"49","author":"Clark","year":"2014","journal-title":"Health Services Research"},{"key":"10.1016\/j.josat.2023.208981_bb0025","series-title":"Medications for Opioid Use Disorder Save Lives","first-page":"25310","author":"Board on Health Sciences Policy","year":"2019"},{"issue":"4","key":"10.1016\/j.josat.2023.208981_bb0030","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/ADM.0b013e31829727b2","article-title":"Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes","volume":"7","author":"Cunningham","year":"2013","journal-title":"Journal of Addiction Medicine"},{"issue":"2","key":"10.1016\/j.josat.2023.208981_bb0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/jama.2021.7374","article-title":"Use of medications for treatment of opioid use disorder among US medicaid enrollees in 11 states, 2014\u20132018","volume":"326","author":"Donohue","year":"2021","journal-title":"JAMA - Journal of the American Medical Association"},{"issue":"1","key":"10.1016\/j.josat.2023.208981_bb0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/10550887.2011.642758","article-title":"Effect of buprenorphine dose on treatment outcome","volume":"31","author":"Fareed","year":"2012","journal-title":"Journal of Addictive Diseases"},{"issue":"10","key":"10.1016\/j.josat.2023.208981_bb0045","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.josat.2023.208981_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy","volume":"144","author":"Greenwald","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"issue":"11","key":"10.1016\/j.josat.2023.208981_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on \u03bc-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.josat.2023.208981_bb0060","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/ajad.12288","article-title":"Treatment outcomes in opioid dependent patients with different buprenorphine\/naloxone induction dosing patterns and trajectories","volume":"24","author":"Jacobs","year":"2015","journal-title":"The American Journal on Addictions"},{"issue":"2","key":"10.1016\/j.josat.2023.208981_bb0065","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment","volume":"14","author":"Jakubowski","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"4","key":"10.1016\/j.josat.2023.208981_bb0070","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/ADM.0000000000000934","article-title":"Low-threshold buprenorphine treatment in a syringe services program: Program description and outcomes","volume":"16","author":"Jakubowski","year":"2022","journal-title":"Journal of Addiction Medicine"},{"issue":"18","key":"10.1016\/j.josat.2023.208981_bb0075","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"Johnson","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.josat.2023.208981_bb0080","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1176\/ajp.2007.164.5.797","article-title":"A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: A randomized controlled trial","volume":"164","author":"Kakko","year":"2007","journal-title":"The American Journal of Psychiatry"},{"issue":"2","key":"10.1016\/j.josat.2023.208981_bb0085","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s11606-020-06448-z","article-title":"Factors associated with long-term retention in buprenorphine-based addiction treatment programs: A systematic review","volume":"37","author":"Kennedy","year":"2022","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.josat.2023.208981_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.05.002","article-title":"Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap","volume":"103","author":"Krawczyk","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.josat.2023.208981_bb0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1016\/j.josat.2023.208981_bb0100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose Deaths\u2014United States, 2013\u20132019","volume":"70","author":"Mattson","year":"2021","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"5","key":"10.1016\/j.josat.2023.208981_bb0105","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/ADM.0000000000000774","article-title":"Adapting a low-threshold buprenorphine program for vulnerable populations during the COVID-19 pandemic","volume":"15","author":"Nordeck","year":"2021","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2023.208981_bb0110","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7050e3","article-title":"Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls\u2014United States, 2019\u20132020","volume":"70","author":"O\u2019Donnell","year":"2021","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"8","key":"10.1016\/j.josat.2023.208981_bb0120","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/17512433.2019.1635454","article-title":"Buprenorphine treatment for opioid use disorder: Recent progress","volume":"12","author":"Parida","year":"2019","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/j.josat.2023.208981_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108317","article-title":"Adherence to buprenorphine: An analysis of prescription drug monitoring program data","volume":"216","author":"Pizzicato","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2023.208981_bb0130","series-title":"Recovery Support Tools and Resources","year":"2022"},{"issue":"12","key":"10.1016\/j.josat.2023.208981_bb0135","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/add.12315","article-title":"Buprenorphine implants for treatment of opioid dependence: Randomized comparison to placebo and sublingual buprenorphine\/naloxone","volume":"108","author":"Rosenthal","year":"2013","journal-title":"Addiction (Abingdon, England)"},{"issue":"9","key":"10.1016\/j.josat.2023.208981_bb0140","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of Opioid Agonist Treatment with all-Cause Mortality and Specific Causes of death among people with opioid dependence: A systematic review and meta-analysis","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2023.208981_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108710","article-title":"Growing racial\/ethnic disparities in buprenorphine distribution in the United States, 2007\u20132017","volume":"223","author":"Schuler","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2023.208981_bb0150","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.josat.2023.208981_bb0155","article-title":"Medicaid coverage of medication-assisted treatment for alcohol and opioid use disorders and of","volume":"119","author":"Substance Abuse and Mental Health Services Administration","year":"2018","journal-title":"Medication for the Reversal of Opioid Overdose."},{"key":"10.1016\/j.josat.2023.208981_bb0160","series-title":"Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health","first-page":"156","year":"2020"},{"issue":"2S","key":"10.1016\/j.josat.2023.208981_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.josat.2023.208981_bb0170","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"Journal of Addictive Diseases"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923000310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923000310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:39:29Z","timestamp":1762652369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875923000310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":33,"alternative-id":["S2949875923000310"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2023.208981","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Higher buprenorphine dose associated with increased treatment retention at low threshold buprenorphine clinic: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2023.208981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"208981"}}